IP2017 is a proprietary triple reuptake inhibitor of 5-HT, NA, and DA. Initiator has tested IP2017 in rodent models of persistent and neuropathic pain. IP2017 possesses superior antinociceptive efficacy compared with the dual monoamine reuptake inhibitor duloxetine, and it is an attractive new drug candidate for the treatment of chronic pain. In preclinical studies, IP2017 has shown positive effect superior to the drug duloxetine.

Neuropathic pain is a devastating condition that affects millions of patients globally. The market for the symptom was estimated at approximately USD 6.3 billion in 2019 and is expected to increase to approximately USD 10 billion by 2027. It is a multifactorial disease where recommended first-line treatments include selected antidepressants (i.e., tricyclic antidepressants and dual serotonin and norepinephrine reuptake inhibitors), calcium channel alpha2-delta ligands (i.e., gabapentin and pregabalin), and lidocaine. Opioid analgesics and tramadol are generally recommended as the second line treatment, considered for first-line use in specific clinical circumstances. Despite the availability of several different treatment options, less than 50 percent of patients experience meaningful pain relief. With the lack of effective treatments, these areas have a large unsatisfied need, creating opportunities to develop new therapies.

[1] Coherent Market Insights “Neuropathic Pain Market Analysis” (2020), https://www.coherentmarketinsights.com/market-insight/neuropathic-pain-market-3656.

[2] Finnerup, Nanna B., et al. “Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis.” The Lancet Neurology 14.2 (2015): 162-173.

*Both IP2016 and IP2017 have been included in a screening agreement with the US National Institute on Drug Abuse to evaluate their anti-addictive properties. Specifically, NIDA’s Addiction Treatment Discovery Program will work closely with the company to determine the effects of IP2016 and IP2017 on cocaine- and methamphetamine-related behaviors using established preclinical rodent models through its contract resources.